LOS ANGELES, July 22, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has completed enrollment in its Phase 3 clinical trial evaluating arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS) ahead of schedule. The Phase 3 trial of arimoclomol for ALS is a 76-week, randomized, placebo-controlled trial being conducted at 30 centers of excellence in North America and Europe.

LOS ANGELES, May 31, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will commence trading on the OTCQB Venture Market as of Tuesday, June 4, 2019, under the same ticker symbol "CYTR".  Investors can find current financial disclosure and real-time Level 2 quotes for the Company on www.otcmarkets.com/stock/CYTR/quote.

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today announced that effective immediately, Mr. Eric Curtis, President and Chief Operating Officer of CytRx Corporation and President and CEO of Centurion BioPharma Corporation, is stepping down to pursue another opportunity. Both roles at the appropriate time will be reviewed with the Board of Directors and decisions will be made regarding a replacement.

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that ImmunityBio and NantKwest announced the initiation of a Phase 2 randomized, two-cohort, open-label study for first and second-line treatment of locally advanced or metastatic pancreatic cancer (QUILT-88). The study has received FDA authorization and will initially enroll 268 subjects across both cohorts. They indicated enrollment expected to begin in June 2020.

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today clarified certain prior disclosures regarding its relationship with Orphazyme A/S. As previously reported, in 2011 CytRx agreed to sell and transfer certain data, intellectual property rights and other assets, including contractual rights and obligations relating to a portfolio of chemical compounds, including arimoclomol, to Orphazyme A/S, which sale included conditional future payments to CytRx contingent upon the achievement of specified clinical/regulatory and sales milestones as well as single and double digit royalty payments, depending on the indication.

LOS ANGELES, June 19, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing principally in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has updated the anticipated timing for submission of its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval for arimoclomol in Niemann-Pick disease Type C (NPC).  Based on advice received from the EMA's Scientific Advice Working Group, Orphazyme expects to submit the arimoclomol MAA in the first half of 2020.

Licensee Orphazyme A/S Rapidly Completes Enrollment in Clinical Trials for Multiple Indications and Prepares for Regulatory Submissions LOS ANGELES , Aug. 9, 2019 /PRNewswire/ -- CytRx Corporation (OTCQB: ...

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted Orphazyme's recently published data from its double-blinded Phase 2 trial of arimoclomol for the treatment of Sporadic Inclusion Body Myositis (sIBM). This was a 24-patient randomized pilot trial (16 patients on arimoclomol and 8 on placebo) where 83% of arimoclomol treated patients were stabilized versus 25% on placebo. Four months of continuous treatment resulted in a 60% reduction in progression, and at 8 months (4 months after treatment discontinuation), there was a 75% reduction in progression.

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company, today highlighted that ImmunityBio, previously NantCell, Inc., and NantKwest announced a complete response in Metastatic Pancreatic Cancer in one patient who received its experimental Human Killer Cell combination Immunotherapy, which includes aldoxorubicin, in its Phase 1 clinical trial. This result builds on the results released previously in patients with Triple Negative Breast Cancer ("TNBC"), in which two of nine patients treated with this experimental cancer therapy also had a complete response. These immunotherapies include CytRx's aldoxorubicin as part of its innovative chemoradiation therapy. NantKwest also indicated they plan to initiate registration trials in recurrent metastatic TNBC and pancreatic cancer patients that failed standard of care.

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company, today highlighted Orphazyme A/S received FDA Breakthrough Therapy Designation for arimoclomol for NPC. Breakthrough Therapy Designation is a program intended to expedite the development and review of drugs to treat serious or life-threatening diseases in cases where preliminary clinical evidence shows that the drug may provide substantial improvements over available therapy.

Patent Covers the Formulation, Storage, Delivery and Administration of Aldoxorubicin at Room Temperature and Eliminates the Need for Cold Handling LOS ANGELES , June 26, 2019 /PRNewswire/ -- CytRx Corporation ...

LOS ANGELES, July 30, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology and rare diseases, today highlighted that following a positive meeting with the U.S. Food and Drug Administration (FDA), arimoclomol licensee Orphazyme A/S (ORPH.CO) remains on track to submit a New Drug Application (NDA) for arimoclomol in Niemann-Pick Disease Type C (NPC) in the first half of 2020. Orphazyme also announced plans to introduce an Early Access Program for NPC in the fall of 2019.

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has provided updated clinical and regulatory guidance on arimoclomol milestones through 2021 in its four indications, amyotrophic lateral sclerosis (ALS), sporadic Inclusion Body Myositis (sIBM), Niemann-Pick disease Type C (NPC) and Gaucher Disease. Pre-clinical work has also commenced in Parkinson's Disease.

LOS ANGELES, CA / ACCESSWIRE / June 27, 2019 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Eric L. Curtis, President and COO of CytRx Corporation ...

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphazyme A/S (ORPH.CO) has provided updated information regarding its projected filing of a New Drug Application (NDA) for arimoclomol in Niemann-Pick disease (NPC) and its preparation for getting arimoclomol to patients.

CytRx Corporation (OTCQB: CYTR), a biopharmaceutical research and development company specializing principally in oncology and neurodegenerative diseases, today highlighted that Orphayzme A/S announced they have received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the development of arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS).